ePI

Market Access

The benefits of ePI for patients and the planet

With one change made by one pharmaceutical company, we could save half a million trees every year. Imagine the impact if the change was made across industry.

Market Access

Exploring the potential of FHIRs and e-labelling

Fast Healthcare Interoperability Resources (FHIRs) allow fast to bu

News

BMS eyes another celmod filing in myeloma after phase 3 win

Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks